
SRUJANA CHERUKURI, Ph.D.
Chief Executive Officer
Before becoming CEO, Dr. Cherukuri served in multiple roles at Noble Life Sciences including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs. In her previous roles at Noble, Dr. Cherukuri was instrumental in optimizing new preclinical animal models and streamlining operations to achieve operational efficiency. In addition, Dr. Cherukuri led the successful consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri has expertise in diverse areas of Biology and has 12+ years of research experience in the areas of oncology and stem cell biology. Dr. Cherukuri completed her PhD in biology at Cleveland State University.

ALAIN CAPPELUTI, CPA
President
Mr. Cappeluti has more than 30 years of experience in finance and public accounting for private and public companies, with more than 20 of those years spent in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. As the second employee of HGS in 1992 at the start of the human gene sequencing effort, he held positions of increasing responsibility and served for many years as Vice President of Finance. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. He led one of the largest real estate transactions in Maryland history while at HGS when the company executed a sale lease back on its corporate headquarters and large scale GMP manufacturing facilities. Mr. Cappeluti was part of the team that spun out Cogenesys from HGS in 2006 and was the CFO until the company was sold to Teva Pharmaceuticals in 2008. As a customer of CRO services in previous biotechnology industry positions, Mr. Cappeluti developed a keen awareness of quality and service issues that inform his leadership at Noble. He also serves on the board of O-Traces, Inc., an early stage cancer diagnostics company, and is a consultant to other life science companies.

STEPHEN K. HORRIGAN, Ph.D
Chief Scientific Officer
Dr. Horrigan is an accomplished molecular geneticist who is known for his contributions to the development of innovative approaches for using genomic profiles and biomarkers to enhance drug discovery and development. Prior to joining Noble, Dr. Horrigan was the Vice President of Research at Avalon Pharmaceuticals a wholly-owned subsidiary of Clinical Data, Inc. During his tenure at Avalon, he held several positions of increasing responsibility within the research organization while directing both internal and collaborative research programs. He also played a key leadership role in the development of the company’s unique genomic biomarker-driven R&D platform. Dr. Horrigan has a strong expertise in the cellular control mechanisms of cancer and the use of biomarkers for the discovery and development of therapeutics and has multiple publications and patents in this area. Prior to joining Avalon, Dr. Horrigan was Associate Professor in the Department of Pediatrics and Lombardi Cancer Center at Georgetown University Medical Center where he led a research group focused on cancer genomics and the application of biomarkers in cancer diagnostics. He has also held positions at the University of Illinois, College of Medicine and the University of Chicago School of Medicine.

KENNETH C. CARTER, Ph.D.
Chairman
Dr. Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He co-founded Avalon Pharmaceuticals, Inc. in January 1999 and served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During this time, Avalon developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to that, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he worked for several years and played a role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter has served on the boards of directors for multiple biotechnology industry organizations including the Maryland Health Care Product Development Corporation and the National BIO Industry Organization. He also served recently as a special advisor to the Maryland Governor’s Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.

TODD PARSLEY, Ph.D.
Director of Infectious Diseases
Dr. Parsley has over twenty years experience in microbiology, molecular biology and infectious disease research with an emphasis on pathogen-host interactions, viral replication/gene expression and pathogen resistance. He directs and manages research projects for development of antimicrobial agents for viruses, bacteria, and fungi for both internal research and contract research services. He also leads Noble’s Hepatitis Virus research programs. At Noble, Dr. Parsley develops, modifies, and optimizes molecular assays for use in the identification, detection, and quantification of infectious organisms and host gene expression.

RIGOBERTO SANCHEZ, Ph.D., RQAP-GLP
Associate Director of Quality Assurance
Dr. Sanchez has 25+ years of laboratory animal and pre-clinical research experience. He has directed and managed FDA/EPA-compliant GLP studies and has served in the roles of study director, study administrator, and quality assurance. Dr. Sanchez has also served as Chair and Vice-Chair of the GLP University Subsection for the Society of Quality Assurance and is a former faculty member in the Department of Pathology, Medicine, at the University of Maryland School of Medicine.

ROBYN E. SHAW, M.S.
Associate Director of Operations
Ms. Shaw has 20+ years of experience in the contract research industry with a broad perspective in research toxicology, immunology, and infectious diseases. She has extensive knowledge in preclinical studies in acute, subacute, and chronic toxicity in GLP environments. She also is knowledgeable of regulatory documents including The Guide for the Care and Use of Laboratory Animals, The Animal Welfare Act, Public Health Service Policies, the AVMA Guidelines, and the US FDA’s GLPs. Prior to joining Noble, she was the Director of Preclinical Services at Spring Valley Laboratories, Inc.

STEVEN SHIPLEY, D.V.M., DCLAM
Attending Veterinarian
Dr. Shipley has spent 20 years as a full-time Laboratory Animal Veterinarian conducting research and supporting studies in infectious disease/vaccine development, genetic disorders, transplant immunology, medical device development, pharmacology/drug development, and cancer research. He is a Diplomate of the American College of Laboratory Animal Medicine and has an emphasis on large animal surgical models and animal program management.

BIDI BOLARIN, M.P.A
Human Resources Manager
Bidi Bolarin, M.P.A has 22 years of experience in telecommunications, electricity regulations, and human resources. She graduated with JD from the University of Ilorin, Nigeria, and she has a Masters in Public Administration, with a Human Management concentration, from Rutgers University Camden, NJ. Prior to Noble, she was a Human Resources Manager at Clover Contracting LLC.

Ivan Tatarov, D.V.M.
Clinical Veterinarian
Dr. Tatarov has 15+ years of experience in Laboratory Animal Medicine. He provides veterinary medical care and utilizes a variety of laboratory animals in medical research in compliance with Federal regulations and Good Laboratory Practice. Prior to Noble Life Sciences worked as a clinical research veterinarian at the University of Maryland School of Medicine.

SRUJANA CHERUKURI, Ph.D.
Chief Executive Officer

Alain Cappeluti, CPA
President

STEPHEN K. HORRIGAN, Ph.D.
Chief Scientific Officer

KENNETH C. CARTER, Ph.D.
Chairman

TODD PARSLEY, Ph.D.
Director, Infectious Diseases

RIGOBERTO SANCHEZ, Ph.D., RQAP-GLP
Associate Director of Quality Assurance

Robyn E. Shaw, M.S.
Associate Director of Operations

Steven Shipley, D.V.M., DCLAM
Attending Veterinarian

Bidi Bolarin, M.P.A
Human Resources Manager
Lead Scientists

Pang-Kuo Lo, Ph.D. MSc
Team Lead, Assay Development

Arundhati Ghosh, Ph.D., MSc
Study Director

Ali Mohammadabadi, Ph.D.
Study Director

Ivan Tatarov, D.V.M.
Clinical Veterinarian

Yongping Chen, M.D., Ph.D.
Senior Study Director

Janet Olugbodi, MSc., Ph.D.
Study Director – Pharm/Tox
Sales

Edwin Gershom, Ph.D.
Business Development Manager
Senior staff with extensive drug, cell and gene therapy, vaccine and medical device development experience
Senior Management
Ph.Ds., 25+ years of animal research and industry experience
Study Directors
Ph.Ds., DVMs, & MS, 20+ years of GLP experience
Technical Staff
BS/BA & AALAS Certified, 10+ years of animal experience
Veterinarian & Surgeons
Ph.Ds., 25+ years of animal research and industry experience
Quality Assurance Manager
Ph.Ds., 25+ years of animal research and industry experience
Our PhD and Masters level scientists will guide you through the study process while our ALAT, LAT, and rLATg technicians will meet the technical requirements of your study. Our quality assurance professionals and veterinarians have over 25 years of experience in the industry.
We encourage and provide resources for staff to continually obtain additional training, including AALAS certification at job-appropriate levels.
Learn more about our values and mission
Resources & White Papers
PASSIONATE ABOUT COLLABORATING FOR A CURE
Orthotopic Liver Cancer Model Established in Athymic Nude Mice
Introduction The study aims to establish an orthotopic liver cancer model in nude mice and evaluate the anti-tumor efficacy of Sorafenib. Liver cancer is a leading cause of...
Mouse Peritonitis/Sepsis Model of MRSA Infection
Noble Life Sciences, in collaboration with ImQuest Biosciences, has optimized the peritonitis/sepsis mouse model to screen for new antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). The model’s popularity derives from its ease of use with small and expensive animals, short-duration experiments with reproducible infections, and simple end-points.
Animal Models for the Development of Vaccines and Therapeutics for Influenza Infections
The mouse and ferret animal models are the most widely used models for influenza studies. Each has...
Immunophenotyping of Tumor-Infiltrating Immune Cells in Mouse Syngeneic Tumor Models Using Multi-Color Flow Cytometry Assays
The in vivo animal tumor models possessing fully functional immunity are essential for preclinical research of new immunotherapeutic medicine. Syngeneic tumor models are...